The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

Abstract

The expression of costimulatory molecules such as CD70 or CD80 by gene -modified tumor cells has been shown to enhance the antitumor immune response based mainly on T lymphocytes. However, most human tumors show defects of major histocompatibility complex ( MHC ) expression, preventing them from being recognized by MHC -restricted T cells. To investigate if coexpression of CD70 and CD80 costimulatory molecules induces comparable antitumor responses in low and high MHCexpressing tumor cells, we used two low immunogenic murine tumor models, the B16.F10 melanoma and the TS / A mammary adenocarcinoma cell lines expressing, respectively, low and high levels of MHC class I molecules. Transfection of both CD70 and CD80 genes resulted in an increased capacity of gene -modified tumor cells to costimulate in vitro the proliferation and cytokine production of optimally activated lymphoid cells. Coexpression of CD70 and CD80 by the two tumor cell lines, TS / A and B16.F10, resulted in both cases in partial regression of subcutaneous tumors. Immunochemical analysis and studies in nude mice showed that, even in the B16.F10 model, T cells had a significant role in the antitumor response induced by combining CD70 and CD80. However, rejection of the CD70 / CD80 -transfected tumor cells appeared more effective in the MHC class I high TS / A model, leading to a protection against parental tumor cells. B16.F10 and TS / A transfectants were then tested with fibroblasts genetically modified to secrete interleukin -12 ( IL -12 ) as a therapeutic vaccine in mice bearing parental tumors. In the two models tested, the injections of irradiated IL -12 and CD70 / CD80 gene -modified cells generated an antitumor response to established tumors leading to the slowing down of the tumor growth rate. Although the mechanisms remain to be defined, these findings suggest that the combination of several immuno -modulatory molecules could provide additional strategies for cancer immuno -gene therapy, even for MHC expression ± deficient tumors. Cancer Gene Therapy ( 2000 ) 7, 1543 ± 1556

CD70 Signaling Is Critical for CD28-Independent CD8+ T Cell-Mediated Alloimmune Responses In Vivo

“…In addition, two separate groups recently reported that coexpression of CD70 and B7-1 on tumor cells enhances antitumor immune responses (63,64). Our data clearly demonstrate that CD27-CD70 is also a critical costimulatory pathway for CD8 ϩ T cell-mediated alloimmune responses.…”

The CD70/CD27 Pathway Is Critical for Stimulation of an Effective Cytotoxic T Cell Response against B Cell Precursor Acute Lymphoblastic Leukemia

“…It is the capacity to trigger expansion of effector T cells by which CD70 recommends itself as a highly relevant costimulatory signal, as documented by a number of murine models for cancer vaccines (42)(43)(44). Our own data showed that in leukemic mice, CD70 expressed by the vaccine cells does indeed induce a potent antileukemic response, which is predominantly mediated by CD8 ϩ cells.…”

In vitro evidence for a new therapeutic approach in renal cell carcinoma

“…In several studies, high expression of CD70 has been found in malignant lymphomas and nasopharyngeal tumors (18) and in all examined clear cell tumors, whereas no expression occurred in the related normal epithelial cells.…”